

17. (Amended) A polypeptide as defined in claim 16, having a molecular weight of about 35 to 50 kDa.

18. (Amended) A polypeptide as defined in claim 17, having a molecular weight of about 43 kDa.

19. (Twice Amended) An isolated polypeptide including a site which is receptive to imidazoline compounds, said polypeptide containing an amino acid sequence shown in SEQ ID NO: 5.

20. (Amended) A polypeptide as defined in claim 19, having a molecular weight of about 50 to 80 kDa.

REMARKS

Claims 16-24 and 37-38 are pending. Applicant has amended the first paragraph of the Specification to update the status of related applications. Applicant has not corrected the oath because divisional applications under 37 C.F.R. §1.53(b) do not require corrected oaths. Applicant notes the finality of the restriction requirement, and reserves the right to pursue non-elected claims in a separate application.

Claims 16-21, 23, 24, 37 and 38 were rejected under 35 U.S.C. §112, first paragraph. Claims 16-20 have been amended. Applicant believes that the present amendments obviate the rejection under 35 U.S.C. §112, first paragraph, withdrawal of the same is respectfully requested.

Claims 16-18, 22-24 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting in view of Claims 26-33 of co-pending application Serial No. 09/389,487. A terminal disclaimer and the

appropriate fee are submitted herewith, obviating the provisional rejection, withdrawal of the same is respectfully requested.


Applicant submits that pending Claims 16-24 and 37-38 are now in order for allowance, prompt and favorable action on the same is requested.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #147/37315D2).

Respectfully submitted,

June 18, 2002



J. D. Evans
Registration No. 26,269
Olivia A. Tolan
Registration No. 45,161

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844

JDE:OAT:sbh

MARKED-UP VERSION OF AMENDMENTS

IN THE SPECIFICATION:

Please amend the paragraph at page 1, lines 4-7 as follows:

This application is a division of application Serial No. 09/922,635, filed September 3, 1997, U.S. Patent No. 6,015,690, which is a continuation-in-part of application Serial No. 08/650,766, filed May 20, 1996, U.S. Patent No. 6,033,871, which is related to provisional application Serial No. 60/12,600, filed March 1, 1996, abandoned.

IN THE CLAIMS:

Please amend Claims 16-20 as follows:

16. (Twice Amended) An isolated polypeptide including a site which is receptive to imidazoline compounds, said polypeptide containing an amino acid sequence [with at least 90% sequence identity with the amino acid sequence] shown in SEQ ID NO: 6[, wherein the percent identity is determined using the BLASTP program with default parameters].

17. (Amended) A polypeptide as defined in claim 16, having a molecular weight of about 35 to [45] 50 kDa.

18. (Amended) A polypeptide as defined in claim 17, having a molecular weight of about [37] 43 kDa.

19. (Twice Amended) An isolated polypeptide including a site which is receptive to imidazoline compounds, said polypeptide containing an amino acid sequence [with at least 90% sequence identity with the amino acid sequence] shown in SEQ ID NO: 5[, wherein the percent identity is determined using the BLASTP program with default parameters].

20. (Amended) A polypeptide as defined in claim 19, having a molecular weight of about [60 to 85] 50 to 80 kDa.